FDA Approves TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) Supplemental New Drug Application (sNDA) to include data for the Reduction of COPD Exacerbations and Hospitalizations - Business Wire

FDA Approves TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) Supplemental New Drug Application (sNDA) to include data for the Reduction of COPD Exacerbations and Hospitalizations  Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Circassia Pharmaceuticals Inc. (“Circassia” or “the Company”), announced today that the US Food and Drug ...